论文部分内容阅读
目的：探讨重组促红细胞生成素（ｒＨｕＥＰＯ）替代治疗慢性肾功能衰竭（ＣＲＦ）贫血患者的红细胞质量改变。方法：选择４３例ＣＲＦ维持性血透贫血患者，２４例应用ｒＨｕＥＰＯ治疗，１９例应用输血治疗，分别观察两组治疗前、后，血红蛋白（Ｈｂ）、血球压积（Ｈｃｔ）、脂质过氧化物（ＬＰＯ）、超氧化物岐化酶（ＳＯＤ）和Ｎａ＋－Ｋ＋ＡＴＰａｓｅ活性变化以及分析Ｎａ＋－Ｋ＋ＡＴＰａｓｅ活性与ＬＰＯ，ＳＯＤ之间相关性。结果：治疗后两组Ｈｂ、Ｈｃｔ均显著升高，ｒＨｕＥＰＯ组ＬＰＯ显著下降（Ｐ＜０．０５），ＳＯＤ和Ｎａ＋－Ｋ＋ＡＴＰａｓｅ活性显著升高（Ｐ＜０．０５）。输血组ＬＰＯ，ＳＯＤ和Ｎａ＋－Ｋ＋ＡＴ－Ｐａｓｅ活性差异不显著，并且Ｎａ＋－Ｋ＋ＡＴＰａｓｅ与ＬＰＯ水平呈显著负相关（ｒ＝－０．４９１，Ｐ＜０．０５），ＳＯＤ活性呈正相关（ｒ＝０．４１３，Ｐ＜０．０５）。结论：ｒＨｕＥＰＯ、输血均能纠正ＣＲＦ患者贫血，增加红细胞数量，前者并能改善红细胞质量，但后者不能。
Objective: To investigate the changes of erythrocyte quality in patients with chronic renal failure (CRF) anemia treated with recombinant rHuEPO. Methods: Forty-three CRF patients with hemodialysis were selected. Twenty-four patients were treated with rHuEPO and 19 patients were treated with blood transfusion. Hb, Hct and lipid peroxidation (LPO), superoxide dismutase (SOD) and Na + -K + ATPase activity and the correlation between Na + -K + ATPase activity and LPO and SOD. Results: The levels of Hb and Hct in both groups were significantly increased after treatment, LPO in rHuEPO group was significantly decreased (P <0.05), SOD and Na + -K + ATPase activity was significantly increased (P <0.05). There was no significant difference in the activity of LPO, SOD and Na + -K + AT-Pase in blood transfusion group, and there was a significant negative correlation between Na + -K + ATPase and LPO level (r = -0.491, P <0.05) .413, P <0.05). Conclusion: Both rHuEPO and blood transfusion can correct anemia and increase the number of red blood cells in CRF patients. The former can improve the quality of red blood cells, but the latter can not.